Scynexis, Inc. is a biotechnology company focused on developing and commercializing innovative antifungal therapies for difficult-to-treat and often life-threatening infections. Its core activity centers on a novel class of triterpenoid antifungal agents designed for both oral and intravenous administration, targeting conditions such as vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis, and other refractory invasive fungal infections. Scynexis works to address significant unmet medical needs in infectious disease, providing options where resistance, toxicity, or limited efficacy constrain existing treatments. The company collaborates with healthcare providers, hospitals, and specialists in infectious diseases and women’s health, positioning its therapies for use in both acute care and outpatient settings. Headquartered in Jersey City, New Jersey and founded in 1999, Scynexis operates within the global biopharmaceutical market as a niche anti-infective developer, contributing specialized expertise to the broader ecosystem of anti-infective research and treatment.